Oral GLP-1 Pill Shows Promise in Helping Zepbound Users Keep the Weight Off
There has been a lot of buzz lately around Zepbound and what happens after people successfully lose weight using injectable GLP-1 medications. Now, a new development from Eli Lilly is adding an interesting twist to that conversation. A once-daily oral pill called orforglipron has been shown to help people maintain their weight loss after switching away from injections like Zepbound or Wegovy, and this is being described as a first-of-its-kind result.
The findings come from a Phase 3 clinical trial known as ATTAIN-MAINTAIN. In this study, people who had already lost significant weight using injectable GLP-1 therapies were switched to either the oral pill orforglipron or a placebo. The big question was whether weight loss could actually be maintained once injections were stopped. According to the results, it clearly could.
Also Read:- Kim Tate Faces a Lonely and Unsettling Christmas in Emmerdale
- A Once-in-a-Lifetime Visitor: Interstellar Comet 3I/ATLAS Says Goodbye
Over the course of 52 weeks, participants who switched to orforglipron were able to maintain nearly all of the weight they had previously lost. For people coming off Wegovy, the average weight regain was less than one kilogram, which is remarkably small. Those who had been on Zepbound also maintained most of their weight loss, with results that were far better than those seen in the placebo group. In contrast, people who did not receive the oral medication regained a significant amount of weight over time.
This matters because obesity is widely recognized as a chronic condition, not something that simply ends once weight is lost. For many people, the hardest part is not losing weight, but keeping it off long term. Until now, most maintenance strategies relied on continued injections, which can be inconvenient or difficult for some patients. The idea that someone could switch directly from a weekly injection to a daily pill, without losing progress, is being seen as a potential game-changer.
The trial also showed that the safety profile of orforglipron was consistent with earlier studies. Most side effects were related to the digestive system and were generally mild to moderate. Importantly, no new safety concerns were identified, and very few participants stopped treatment because of side effects.
Eli Lilly has already submitted orforglipron to the U.S. Food and Drug Administration for approval as a treatment for obesity. If it is approved, this pill could offer a more convenient long-term option for people who have used medications like Zepbound to lose weight and are looking for a sustainable way to maintain those results.
In simple terms, this study suggests that weight loss achieved with powerful injectable drugs does not have to be lost once the injections stop. With an oral alternative like orforglipron, long-term weight management may become easier, more flexible, and more accessible for millions of people.
Read More:
0 Comments